Pancreatic cancer life expectancy — what the figures do and do not tell you

Almost everyone searches for pancreatic cancer life expectancy within a day or two of the diagnosis, usually late at night and usually alone. It is the most human thing in the world to look for. It is also the number most often misread, because of what it was built to do. A life expectancy figure describes a large group of people diagnosed some years ago. It was never designed to forecast one person's course, and it cannot do it.

Almost every figure you will find quoted is a median. A median is the middle point of a group: half the people counted lived longer than it, and some of them lived very much longer. It is a marker in the middle of a wide spread, not a limit and not a date. So when someone asks how long pancreatic cancer takes to run its course, the honest answer begins by asking which group the figure came from, and whether that group looks anything like the person asking.

There are four specific reasons a published figure tends to mislead the person reading it. It is historical — years have to pass before the figure can be calculated at all, so everyone inside it was treated with what was available long before it was published. It is averaged — a tumour that was removed completely and a tumour that had already spread widely sit inside the same headline number. It mixes tumour types — slow-growing neuroendocrine tumours are sometimes pooled with ductal adenocarcinoma, which behaves very differently. And it describes a group, not a person. Pancreatic cancer survival by stage takes each stage figure apart and shows what it does and does not contain.

None of this makes the figures worthless. It makes them the opening of a specific conversation rather than an answer on their own. The rest of this page explains what genuinely shapes the time ahead, and the questions that turn a number into something about your own situation. If you are still getting your bearings after the diagnosis, the complete pancreatic cancer guide covers diagnosis, treatment and support in one place.

• Which group does that number come from? Ask whether it describes people whose tumour was removed, people treated for advanced disease, or everyone pooled together. The answer changes what the figure is worth to you.
• Is this ductal adenocarcinoma or a neuroendocrine tumour? Ask for the exact wording on the pathology report. The two are classified, staged and treated separately, and their outlooks are not comparable.
• Is my tumour resectable, borderline, locally advanced or metastatic? This category, rather than the stage number alone, is what decides whether an operation is on the table now, later, or not at all.
• If treatment works, could an operation become possible? Downstaging a borderline tumour into the operable group is a real objective, not a hope. It is worth asking explicitly rather than assuming the first answer is the final one.
• What would you expect over the coming months, and what would change it? A time frame given with its conditions attached is far more useful than a bare figure, and far easier to plan around.
• If it has already spread, what does living with it actually involve? Living with advanced (metastatic) pancreatic cancer sets out what treatment aims for when the goal is control rather than cure.

1. 1

   Confirm what the tumour actually is

   The pathology report decides whether adenocarcinoma information applies to you at all. Tissue is usually obtained by endoscopic ultrasound with a fine-needle sample.

   Biopsy coordinated with specialist endoscopy partners
2. 2

   Establish the resectability category

   A pancreatic-protocol contrast CT is read specifically for the tumour's relationship to the arteries and veins behind the pancreas. This finding shapes the answer more than the stage label does.

   Ordered and reported in-house at CION
3. 3

   Baseline the markers and your general condition

   CA 19-9 and routine bloods are taken at the outset so the trend can be followed, alongside an honest look at weight, appetite, digestion and how well you are in yourself.

   In-house at CION
4. 4

   Discuss the case as a team

   Scans, pathology and general health are reviewed together rather than by one doctor alone, so the plan reflects what medical oncology, radiation oncology and the surgical partners each think is achievable.

   Tumour board at CION
5. 5

   Set the plan and the reassessment points

   Chemotherapy, chemoradiation or SBRT is planned around the category, with the dates the plan will be reviewed agreed in advance. Pancreatic cancer treatment in Hyderabad sets out the options in full.

   Systemic therapy and radiation in-house at CION
6. 6

   Answer the question in plain words

   We tell you what the published figures describe, which parts of them apply to your situation and which do not. We will not invent a number, and we will not pretend a group average is a forecast for you.

   Free 45-minute consultation

Being clear about this early saves a difficult conversation later. Your first consultation is free and lasts 45 minutes, and it is a real review of your reports rather than a booking appointment. Bring the scan report and the pathology report if you have them, because those two documents answer more of this question than anything you will read online.

Delivered in-house at CION, across 35+ centres in Telangana and Andhra Pradesh: medical oncology — chemotherapy before surgery, after surgery and for advanced disease; PARP-inhibitor-class maintenance where an inherited BRCA change is found; immune checkpoint inhibitor therapy where the tumour is mismatch-repair deficient; and systemic treatment for neuroendocrine tumours, including somatostatin-analogue-class therapy. Also radiation, chemoradiation and SBRT; the ordering and reporting of pancreatic-protocol CT, MRI/MRCP, CA 19-9 and bloods; genetic counselling; nutrition and pancreatic enzyme replacement; pain relief, psycho-oncology and supportive care; and survivorship follow-up.

Coordinated with specialist HPB, gastroenterology and endoscopy partner centres, and may be billed there: all pancreatic surgery, including the Whipple procedure and distal pancreatectomy; endoscopic ultrasound with biopsy; ERCP and biliary or duodenal stenting; staging laparoscopy; coeliac plexus block for pain; PET-CT and DOTATATE PET; and peptide receptor radionuclide therapy. We arrange these, we take part in the decisions, and we tell you in advance where each one happens and who invoices you. We do not describe them as our own theatre or endoscopy lists, because they are not.

This is a serious cancer and it is often found late. Saying otherwise would be dishonest, and you would see through it. But the picture is less fixed than a headline figure suggests, and for specific reasons. Cure is possible when the tumour is found early and can be removed completely, usually followed by chemotherapy. Systemic treatment given first can shrink a borderline tumour enough to make an operation possible that was not possible at diagnosis. Neuroendocrine tumours carry a considerably better outlook and are treated on an entirely different track. And systemic therapy has moved on, which is precisely why a figure calculated from an earlier era should not be read as a fixed account of the years ahead.

Medical disclaimer: This page explains how pancreatic cancer life expectancy figures are constructed and how to read them, and is reviewed by a CION medical oncologist with reference to NCCN guidance on pancreatic adenocarcinoma and to the WHO classification of digestive system tumours. It is general information and deliberately states no life expectancy or survival figure, because no published figure describes an individual; your own outlook depends on your tumour type, resectability category, general health and response to treatment, and should be discussed with your treating team. Chemotherapy, radiation, chemoradiation and SBRT, imaging and CA 19-9 ordering and reporting, genetic counselling, nutrition and enzyme support, pain relief, psycho-oncology and survivorship care are delivered by CION; all pancreatic surgery, endoscopic ultrasound and biopsy, ERCP and stenting, staging laparoscopy, coeliac plexus block, PET-CT and DOTATATE PET, and peptide receptor radionuclide therapy are coordinated with specialist HPB, gastroenterology and endoscopy partner centres and may be billed there.